|
Patent landscape, scope, and claims: |
Scope and Patent Claims for US Patent 4,917,120 (Smokeless Nicotine Inhaler) and the US Patent Landscape Around Volatile-Nicotine, Porous Polymer Reservoirs, and Nicotine-Miscible Esters
US Patent 4,917,120 claims a smokeless nicotine inhaler built around a porous solid-form synthetic polymer reservoir that holds nicotine + a volatile nicotine-miscible substance with a normal boiling point (bp) range of 175°C to 275°C. The core claim scope is not “nicotine inhalation” broadly. It is tightly tied to (1) the delivery device architecture, (2) the reservoir type (porous solid polymer), and (3) the specific liquid pairings (nicotine with an ester or diol/triol-esterified with a short alkyl carboxylic acid, especially glyceryl triacetate), constrained by weight/weight ratios.
What does US 4,917,120 claim for a smokeless nicotine inhaler?
Immediate claim-construction anchors (from the independent structure appearing in claims 1, 8, 9, and 10):
-
Device geometry
- A housing with a first open end and a mouthpiece open end
- A tubular passageway between them
-
Reservoir form factor
- A reservoir in the passageway
- The reservoir is porous solid-form synthetic polymer (claim 1) or a porous solid-form polymeric reservoir (claims 8–9)
-
Reservoir function
- Reservoir is adapted to contain and liberate volatile nicotine-containing fluid into air passing through the passageway
- The release is by volatilization into the airflow, not by combustion or tobacco burning
-
Composition system
- Nicotine is present as the active volatile component
- A volatile nicotine-miscible substance is present, with:
- wt/wt ratio between about 2.0 and about 10.0 (claim 1)
- normal boiling point between about 175°C and about 275°C
-
Chemical identity narrowing through dependent claims
- Claim 2: volatile nicotine-miscible substance is an ester
- Claim 4: volatile nicotine-miscible substance is glyceryl triacetate
- Claim 6–7: polymer is a polyolefin, including polyethylene
-
Bioperception/mucosa impact rationale (functional limitation)
- Claim 3: ester “accompanies nicotine vaporized from the reservoir and reduces sensory impact… on oral, pharyngeal or lung mucousal tissue”
-
GRAS-like restriction
- Claim 5: volatile substance is “generally regarded as safe for human consumption”
Functional consequence of claim 1: the combination is designed to modify sensory impact while enabling volatile nicotine delivery via airflow, using a specific volatility window and specific miscible co-solvent class.
How broad is the independent claim scope of US 4,917,120?
Claim 1 scope (device + porous reservoir + nicotine/co-solvent volatility window):
- Device: must be an air-through tubular housing with two open ends
- Reservoir: must be a porous solid-form synthetic polymer
- Co-solvent identity:
- Must be nicotine-miscible and volatile
- Must have bp 175–275°C
- Composition ratio:
- Nicotine : volatile nicotine-miscible substance is 2–10 wt/wt (as recited in the claim language provided)
- Polymer class not limited in claim 1; later narrowed in dependent claims
Claim 8/9/10 scope (alternative composition framing):
- Claim 8: nicotine + diol or triol at least partially esterified with a short-chain alkyl carboxylic acid (<5 carbons), producing an ester with bp 175–275°C, with nicotine and ester wt/wt 0.5–40
- Claim 9: ethanol-derived ester concept (ethanol ester with alkyl carboxylic acid), again bp 175–275°C, nicotine:ester wt/wt 0.5–40
- Claim 10: nicotine + glyceryl triacetate with wt/wt 0.5–40
- Claim 11: narrows claim 10 to 2–10 wt/wt
Practical breadth takeaways
- The invention is broad enough to cover multiple ester chemistries if they meet:
- volatility window (bp 175–275°C),
- nicotine miscibility,
- and reservoir/device form factor.
- It is still narrow relative to “any smokeless nicotine inhaler” because it excludes:
- non-porous liquid chambers,
- non-polymer reservoirs,
- co-solvents outside the bp window,
- and (in dependent claims) specific polymer families and specific esters.
Which chemical co-solvents are explicitly within the claims of US 4,917,120?
Does the claim require an “ester” co-solvent?
- Yes in dependent claim 2: volatile nicotine-miscible substance is an ester
- Independent claim 1 uses “volatile nicotine-miscible substance” with a bp window but does not state “ester” in claim 1 as provided; claim 1 becomes tethered to “ester” via claim 2 and via the structural ester logic in claims 8–10.
Is glyceryl triacetate a covered co-solvent?
- Yes. Claim 4: “volatile nicotine-miscible substance is glyceryl triacetate”
- Claim 10: composition consisting essentially of nicotine and glyceryl triacetate
- Claim 11: wt/wt 2–10 for nicotine and glyceryl triacetate
Are short-chain-alkyl carboxylic acid esters within scope?
- Claims 8–9 cover esters made from:
- diol/triol partially esterified with alkyl carboxylic acid having <5 carbon atoms, and/or
- ethanol with alkyl carboxylic acid (bp 175–275°C), consistent with the ester formation framing.
What does “normal boiling point between 175°C and 275°C” do to claim scope?
The boiling-point range is a claim-limiting property. In enforceable scope terms, a device using:
- a nicotine-miscible co-solvent with bp below 175°C or above 275°C falls outside the claimed volatility window for the independent composition feature (claim 1) and for the bp-restricted ester frameworks (claims 8–9).
Because the claim language is based on normal bp, the scope will turn on:
- what “normal” conditions are accepted in practice (typically standard pressure),
- and whether the co-solvent’s boiling range remains within 175–275°C.
What polymer reservoir types are claimed under US 4,917,120?
Is the reservoir porous and polymeric required?
- Yes. In claim 1 the reservoir is “a porous solid-form synthetic polymer”
- In claims 8–9 it is “porous solid-form polymeric reservoir”
Are polymer types limited?
- Claim 1: porous solid-form synthetic polymer (no specific polymer family)
- Claim 6: polymer is polyolefin
- Claim 7: polymer is polyethylene
Implication for landscape: generic or alternate designs that use:
- metal wicks,
- non-porous polymer films,
- ceramic porous structures,
- or free-liquid reservoirs
can evade scope even if the chemistry matches, because the reservoir architecture is claim-critical.
What is the device claim “air passing through” limitation doing?
The claims repeatedly require:
- “liberate/volatilize into air passing through said passageway.”
This aligns the system with an aerosol-free air-through volatilization concept rather than:
- actively heated coils dedicated to vapor generation,
- direct nebulization,
- or aerosol droplet production mechanisms.
A design that relies on a different airflow-vaporization coupling can avoid literal infringement even if it uses the same liquid pairings.
Which claim elements are most likely to be the focal points in infringement analysis?
Based on the claim structure as provided, the “hot spots” for claim mapping are:
- Porous reservoir is present and is a solid-form polymer (not liquid, not gel, not non-porous).
- Tubular passageway with two open ends connecting to a mouthpiece.
- Co-solvent meets:
- nicotine miscibility,
- bp window 175–275°C.
- Weight ratio constraints (claim-specific):
- 2–10 in claim 1,
- 0.5–40 in claims 8–9 and 10,
- 2–10 in claim 11.
- If asserting dependent claims:
- ester identity (claim 2),
- glyceryl triacetate (claims 4, 10, 11),
- polymer is polyolefin/polyethylene (claims 6–7),
- and functional sensory reduction (claim 3).
How do claim “consisting essentially of” phrases limit scope?
Claims 1, 8–10 use “consisting essentially of” in the inhaler preamble and/or composition recitals.
That typically means:
- the listed elements are required,
- and additional components are permitted only if they do not materially change the basic and novel characteristics.
For competitive freedom-to-operate assessment, that creates a boundary:
- adding flavor agents, humectants, or other volatiles may be outside if they materially change volatility behavior, nicotine miscibility behavior, or the sensory-impact rationale embedded in claim 3.
What is the likely patent landscape around US 4,917,120: which adjacent “families” matter most?
Without adding external numbers not supplied here, the landscape can be characterized at the level that drives licensing and design-around strategy:
1) Volatile nicotine with co-solvent / carrier that modifies sensory impact
- The claimed chemistry is built around:
- nicotine + nicotine-miscible volatile ester(s),
- co-solvent bp window,
- explicit sensory reduction limitation in claim 3.
Landscape relevance: many later nicotine inhaler or smokeless delivery concepts can converge on:
- co-solvent selection,
- mouth-throat-lung irritation reduction,
- and volatility tuning.
2) Solid porous polymer reservoirs
- The architecture constraint (porous solid synthetic polymer reservoir in a tubular airflow path) is a distinct design center.
- Later products using:
- liquid cartridges,
- liquid-filled chambers,
- or non-porous wicking beds
will often not map.
3) Ester class and glyceryl triacetate
- Claim 4 and claims 10–11 make glyceryl triacetate a specific anchor.
- If competitors use glyceryl triacetate with nicotine at covered ratios, they concentrate risk.
4) Polyolefin and polyethylene
- Dependent claims introduce additional design fences:
- if a design uses a different polymer (e.g., fluoropolymers, silicone-based porous matrices, cellulose derivatives), it can avoid those narrower claim paths while leaving the broader claim 1 still in play.
When does US 4,917,120 lose exclusivity in the US?
No filing, grant, or term adjustment data was provided. Without those inputs, an exclusivity/expiration timeline cannot be produced without risking factual errors.
What generic entry risks exist for inhalers using nicotine + glyceryl triacetate?
Highest literal infringement risk region:
- devices that use:
- porous solid polymer reservoirs,
- a tubular airflow path through a mouthpiece,
- nicotine + glyceryl triacetate,
- and nicotine:triacetate wt/wt within claim 10 and/or 11.
Medium risk region:
- nicotine + other esters with bp 175–275°C, if they also meet nicotine miscibility and reservoir and housing requirements (claim 1 + claim 2 logic).
Lower risk region:
- designs that match the chemistry but do not use the porous polymer reservoir architecture, or that use a reservoir but not in the tubular air-flow configuration.
What formulation elements are required vs. optional under the independent claim?
Required (for claim 1 as provided)
- porous solid-form synthetic polymer reservoir
- nicotine + volatile nicotine-miscible substance
- wt/wt ratio 2.0 to 10.0
- normal boiling point 175°C to 275°C
- housing/tubular passageway with open ends and mouthpiece open end
- airflow liberates volatile nicotine into passing air
Dependent narrowing (optional depending on which claim is asserted)
- ester identity (claim 2)
- sensory reduction rationale (claim 3)
- glyceryl triacetate (claim 4)
- GRAS-like restriction (claim 5)
- polyolefin/polyethylene (claims 6–7)
- diol/triol-esterified chemistry (claims 8–9)
- composition consisting essentially of nicotine + glyceryl triacetate with wt/wt 0.5–40 (claim 10)
- nicotine:triacetate wt/wt 2–10 (claim 11)
How does US 4,917,120 compare with likely later smokeless nicotine inhaler design approaches?
Comparison dimension: co-solvent selection
- US 4,917,120 ties co-solvent eligibility to:
- volatility range (175–275°C),
- miscibility with nicotine,
- and ester-based structuring via dependent claims.
- Later approaches that use:
- different volatility windows,
- non-ester carriers,
- or non-miscible carriers
are less likely to map.
Comparison dimension: reservoir medium
- US 4,917,120 requires porous solid polymer reservoirs.
- Later “cartridge” or “liquid chamber” approaches differ fundamentally and may avoid the porous solid polymer limitation.
Comparison dimension: polymer family
- Dependent claims constrain polyolefin and polyethylene.
- Designs using other porous polymer chemistries may avoid those dependent claims.
Key Takeaways
- US 4,917,120 claims a smokeless nicotine inhaler defined by a tubular air-passage housing and a porous solid-form polymer reservoir that volatilizes nicotine + a nicotine-miscible volatile co-solvent into passing air.
- The chemistry is claim-limited by a normal boiling point range of 175°C to 275°C and wt/wt composition ratios.
- The patent’s most enforceable anchors are:
- porous solid polymer reservoir architecture,
- nicotine + volatile nicotine-miscible co-solvent in the bp window,
- and specifically glyceryl triacetate (claims 4, 10, 11).
- Design-around paths typically involve changing one of three levers:
- removing the porous solid polymer reservoir architecture,
- moving co-solvents outside the bp window or changing miscibility/ratio,
- or changing polymer family away from polyolefin/polyethylene (relevant if dependent claims are asserted).
FAQs
-
What co-solvent properties are required to satisfy the claims if glyceryl triacetate is not used?
The co-solvent must be nicotine-miscible, volatile, and have a normal boiling point between 175°C and 275°C, with composition meeting the relevant wt/wt ratio constraints.
-
Does the patent require an ester co-solvent in the broadest independent claim?
Claim 1 as provided recites “volatile nicotine-miscible substance” by property (bp and miscibility). The ester constraint is explicit in dependent claim 2 and in the ester-based formulations in claims 8–10.
-
Can a device with a non-porous liquid nicotine chamber infringe US 4,917,120?
The claims require a porous solid-form synthetic polymer reservoir in the passageway, so non-porous liquid chamber designs do not align with the claimed reservoir limitation.
-
How do the “consisting essentially of” phrases affect formulation design?
They allow additional components only if they do not materially alter the basic and novel characteristics tied to the nicotine/co-solvent volatility system and reservoir behavior.
-
Which dependent claims most directly narrow competitor design space?
Claims 4, 10, 11 (glyceryl triacetate and wt/wt), and claims 6–7 (polyolefin/polyethylene) are the tightest design-space limiters on the facts provided.
References (APA)
- United States Patent 4,917,120. (n.d.). Smokeless nicotine inhaler (claims provided in prompt).
More… ↓
⤷ Start Trial
|
